- Home
- HOTH vs PMN Comparison
HOTH vs PMN Comparison
Compare HOTH & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- PMN
- Stock Information
- Founded
- HOTH 2017
- PMN 2004
- Country
- HOTH United States
- PMN Canada
- Employees
- HOTH N/A
- PMN N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- HOTH Health Care
- PMN Health Care
- Exchange
- HOTH Nasdaq
- PMN Nasdaq
- Market Cap
- HOTH 15.6M
- PMN 16.0M
- IPO Year
- HOTH 2019
- PMN N/A
- Fundamental
- Price
- HOTH $1.29
- PMN $0.54
- Analyst Decision
- HOTH Strong Buy
- PMN Strong Buy
- Analyst Count
- HOTH 3
- PMN 3
- Target Price
- HOTH $4.00
- PMN $4.33
- AVG Volume (30 Days)
- HOTH 230.9K
- PMN 832.5K
- Earning Date
- HOTH 08-12-2025
- PMN 08-13-2025
- Dividend Yield
- HOTH N/A
- PMN N/A
- EPS Growth
- HOTH N/A
- PMN N/A
- EPS
- HOTH N/A
- PMN N/A
- Revenue
- HOTH N/A
- PMN N/A
- Revenue This Year
- HOTH N/A
- PMN N/A
- Revenue Next Year
- HOTH N/A
- PMN N/A
- P/E Ratio
- HOTH N/A
- PMN N/A
- Revenue Growth
- HOTH N/A
- PMN N/A
- 52 Week Low
- HOTH $0.65
- PMN $0.38
- 52 Week High
- HOTH $3.80
- PMN $1.59
- Technical
- Relative Strength Index (RSI)
- HOTH 50.80
- PMN 42.86
- Support Level
- HOTH $1.22
- PMN $0.51
- Resistance Level
- HOTH $1.31
- PMN $0.73
- Average True Range (ATR)
- HOTH 0.08
- PMN 0.07
- MACD
- HOTH -0.00
- PMN -0.02
- Stochastic Oscillator
- HOTH 57.69
- PMN 11.26
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.